Executive Summary
Real-world TriClip data from the STS/ACC TVT Registry — 3,035 patients across 278 US sites with 98% device success and 1.4% 30-day mortality — validate the ESC 2025 Class IIa upgrade for transcatheter tricuspid therapy and expose the ACC/AHA 2020 silence on this indication as untenable. An 8-year ACURATE neo durability cohort (N=758) showed only 2.1% severe SVD and 3.2% bioprosthetic valve failure, and a propensity-matched conduction system pacing analysis in post-TAVR pacemaker recipients (N=706) cut 1-year death or HF hospitalization nearly in half (HR 0.48). These findings tighten the case for transcatheter therapy across all three valves — but only where guideline-anchored patient selection holds.
- TriClip real-world 30-day mortality of 1.4% with 87% achieving moderate-or-less TR, though only 51% reached mild-or-less — a gap from TRILUMINATE that reflects sicker patients and site learning curve (TCTMD).
- Bayesian meta-analysis of three RCTs (N=1,156) found pre-TAVI PCI yielded no mortality, MI, or stroke benefit and trended toward more major bleeding (RR 1.57) (Canadian Journal of Cardiology).
- Persistent severe TR after M-TEER carried a 5.25-fold mortality hazard — but only in patients ineligible for staged TTVI, sharpening the case for anticipatory tricuspid planning (Structural Heart).
- FDA cleared Laplace Interventional's pivotal TTVR trial, adding a third replacement platform to a market TRISCEND II opened (MD+DI).
- JenaValve released Trilogy TAVR outcomes in pure aortic regurgitation and LVAD populations — the ESC 2025 Class IIb TAVI-for-AR indication is where this platform lives (MassDevice).
What to watch: Edwards Lifesciences reports Q2 earnings July 23, with structural heart growth trajectory the key read-through after CMS's proposed expansion of TAVI coverage to asymptomatic patients.
Aortic Valve (TAVR/TAVI)
Long-term self-expanding TAVR durability data continue to accumulate favorably, but the framing question remains: how much of the outcome is valve, how much is patient? An 8-year ACURATE neo multicenter cohort (N=758 in the durability arm, median age 82, 61% female) reported cumulative incidences of 3.5% moderate SVD, 2.1% severe SVD, and 3.2% BVF at 8 years. Mean gradient held at 6 mmHg with EOA of 1.7 cm². The numbers are favorable — but with 67.3% mortality by 8 years, the durability signal reflects survivor bias in an elderly cohort. This is the same interpretive problem flagged in TCTMD's coverage of 10-year TAVI data from New York Valves 2026. Registry data on younger biological SAVR recipients aged 50-70 show mechanical prostheses outperform bioprosthetics on long-term survival, with 19mm bioprostheses performing worst — a durability comparator TAVR cannot yet match at equivalent age; the ACC/AHA 2020 preference for SAVR under 65 is grounded in exactly this gap.
A Bayesian meta-analysis of three RCTs (N=1,156) found pre-TAVI PCI produced no benefit for MI (RR 0.83), all-cause mortality (RR 0.92), or stroke (RR 0.71), with a signal toward more bleeding (RR 1.57). Selective, lesion-guided PCI wins over routine intervention. A propensity-matched conduction system pacing analysis (N=706) showed CSP cut 1-year death or HF hospitalization to 10.8% vs 20.9% for RV pacing (HR 0.48). [NOTABLE] A separate prospective ECG-based discharge algorithm in 664 pacemaker-naive TAVR patients cut prophylactic TPM use from a consensus-suggested 39.2% to 4.5%, with a 2.0% 30-day readmission for PPM — operational efficiency without safety compromise. The JenaValve Trilogy data in AR and LVAD patients sits squarely in ESC 2025 Class IIb territory for inoperable AR — an indication ACC/AHA 2020 does not address.
Mitral Valve (MitraClip, PASCAL, TMVR)
Persistent tricuspid regurgitation after M-TEER is common (16.3% at 3 months) and prognostically ominous — but the risk concentrates in patients ineligible for staged TTVI. A dual-center retrospective cohort of 905 M-TEER patients (non-randomized, follow-up echo in only 50%) found TTVI-ineligible patients with persistent severe TR had 2-year survival of 39.5%, versus 82.9% in TTVI-eligible patients — statistically indistinguishable from those without persistent TR. Multivariable HR for TTVI ineligibility was 5.25 (95% CI 1.39-19.8). Female sex independently predicted TR persistence. Baseline anticipation of TR trajectory and TTVI candidacy should now be part of M-TEER planning. ESC 2025 Class IIa endorses transcatheter tricuspid therapy for high-risk symptomatic severe TR; ACC/AHA 2020 makes no equivalent recommendation — and this dataset illustrates the cost of leaving that gap unaddressed at the time of the index mitral procedure.
An Annals of Thoracic Surgery editorial asks whether large mitral annuli in TMVR candidates signal advanced disease or limited benefit — a question with direct implications for patient selection as TMVR platforms mature. ESC 2025 rates TMVI for degenerative MS with MAC as Class IIb; the annulus-size question is where that recommendation may sharpen. A staged TAVR-then-TEER case report in a high-risk elderly patient (STS-PROM 12%, EuroSCORE II 15%) with bicuspid AS and functional MR illustrates the pragmatic direction of care — but N=1 does not settle strategy.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] The STS/ACC TVT Registry TriClip analysis presented at New York Valves 2026 is the most consequential tricuspid dataset of the year. Across 3,035 patients at 278 US sites between April 2024 and September 2025 — the first 18 months after FDA approval — device success was 98%, 30-day all-cause mortality was 1.4%, cardiovascular mortality 0.8%, SLDA 1.5%, and 96% of patients discharged home with a median 1-day stay. TR reduction to moderate-or-less reached 87%, though only 51% achieved mild-or-less TR (a gap from TRILUMINATE core-lab data). KCCQ improved by a mean of 22 points; NYHA I/II symptoms rose from 2% to 80%. Limitations: site-reported outcomes without core-lab adjudication, 30-day follow-up only, and a sicker population (50% with prior HF hospitalization vs 25% in TRILUMINATE).
ESC 2025 rates transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR — a recommendation these real-world data operationalize at scale. ACC/AHA 2020 predates the TRILUMINATE, Tri.Fr, and TRISCEND II evidence base and is silent on transcatheter TR; the next ACC/AHA update will have to reconcile this. Contemporary isolated TV surgery cohorts with earlier referral have improved on the historical 8-20% mortality — but no surgical series matches a 1.4% 30-day mortality in this comorbidity profile. That comparison is not a controlled one: surgical series select patients differently, and the ESC 2025 Class IIa specifically targets patients at high surgical risk. Meanwhile, the FDA-cleared Laplace TTVR pivotal trial adds a third replacement platform to the field. Real-world EVOQUE data have already shown 30-day mortality of 3.1% and near-complete TR elimination — better than the TRISCEND II trial, a pattern opposite to what TriClip real-world data show relative to TRILUMINATE.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. Two threads deserve pairing. The 8-year ACURATE neo durability data (2.1% severe SVD) sit alongside surgical bioprosthesis SVD rates that vary by valve size and age. The ESC 2025 shift to TAVI-preferred at ≥70 years leans on exactly this kind of durability signal — but the ACC/AHA 2020 preference for SAVR under age 65 remains anchored in the absence of matched-cohort surgical comparators at these ages. An Annals of Thoracic Surgery piece reframes transapical TAVR as an enabling platform for hybrid heart therapy — a surgical-interventional convergence that reflects where multi-valve disease is heading, as illustrated by today's staged TAVR-plus-TEER case report.
Preprint Highlights
A medRxiv systematic review and meta-analysis (8 cohort studies, N=21,731) estimated the pooled prevalence of epilepsy in children with structural heart disease at 3.0% (95% CI 1.3-4.8%) — substantially above the general pediatric baseline. Heterogeneity was extreme (I² 98%). Cyanotic lesions, complex anatomy, cardiopulmonary bypass, and perioperative neurological injury drove higher prevalence. Neurodevelopmental surveillance belongs in longitudinal care of CHD survivors, not as an afterthought.
Device & Technology
A novel polysaccharide nanocomposite-conjugated hydrogel surface coating for bioprosthetic heart valves integrates anticoagulant, anti-inflammatory, anti-calcification, and pro-endothelialization functions in a single modification, with 2-year room-temperature stability. Preclinical only — but the target problem (glutaraldehyde-crosslinked BHV limitations) is the durability ceiling for both TAVR and SAVR bioprostheses. A Cardiovascular Business report notes the first US patient procedure with a newly FDA-cleared imaging technology in New York — details thin, but structural heart imaging remains the rate-limiting variable in T-TEER outcomes, as multiple New York Valves discussants noted.
Regulatory & Policy
[NOTABLE] CMS's proposed national coverage determination expanding TAVI coverage to asymptomatic patients aligns US reimbursement with the ESC 2025 Class IIa recommendation for early intervention in asymptomatic severe AS with low procedural risk — a threshold built on EARLY TAVR, RECOVERY, AVATAR, and EVoLVeD. The proposed decision memo also permits chart-review triage and adds flexibility to heart team documentation. This is a material expansion of the addressable TAVR population and puts US practice ahead of the pending ACC/AHA guideline update, which has not yet incorporated these trial data. The FDA IDE approval for the Laplace TTVR pivotal trial adds a third replacement platform to a class Edwards' EVOQUE currently leads.
Industry & Market
Edwards Lifesciences profiled its valve innovation pipeline ahead of its July 23 earnings release, spotlighting structural heart demand growth. The narrative is aided by the CMS proposed NCD and TriClip's real-world validation. Abbott — sitting on 24.9% six-month share losses — holds the strongest tricuspid franchise (TriClip) and mitral franchise (MitraClip) despite the stock underperformance. JenaValve's Trilogy TAVR data in AR and LVAD patients (company remains private) targets a niche the ESC 2025 formally opened.
Financial Analysis
Edwards trades at 27.3x forward earnings, roughly double Boston Scientific (11.6x) and Medtronic (12.4x), on the strength of a pure-play structural heart thesis that the CMS asymptomatic-AS NCD reinforces. The July 23 print will show whether TAVR volume acceleration from expanded indications is offsetting durability-driven length-of-hospital-stay compression. Boston Scientific's 54.5% six-month drawdown — despite a strong-buy consensus — reflects sector rotation and specific concerns unrelated to structural heart, but the ACURATE platform (acquired from Symetis) remains a Boston asset that benefits from today's 8-year durability data. Abbott's 24.9% decline coincides with real-world TriClip data that should strengthen, not weaken, the mitral-tricuspid franchise. Anteris (AVR.AX) is up 88% over six months as its DurAVR platform advances toward pivotal readouts.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $91.99 (+1.69%); 6-month: +7.80%
- Market cap: $53.0B | Forward P/E: 27.32 | Beta: 0.87 | 52-week: $72.30-$92.88
- Analyst target: $97.31 (26 analysts) | Recommendation: Buy
- Next earnings: July 23, 2026 (EPS est $0.74, revenue est $1.70B)
- Trading near 52-week highs on structural heart momentum and CMS's proposed NCD expanding TAVI coverage to asymptomatic patients.
Medtronic (MDT)
- Close: $79.20 (+1.24%); 6-month: -16.12%
- Market cap: $101.4B | Forward P/E: 12.37 | Beta: 0.60 | 52-week: $73.31-$106.33
- Analyst target: $97.77 (26 analysts) | Recommendation: Buy
- Next earnings: August 18, 2026 (EPS est $1.39, revenue est $9.55B)
- Evolut low-risk long-term data and expanding indications remain the structural heart tailwind despite broader portfolio drag.
Abbott (ABT)
- Close: $92.18 (+1.59%); 6-month: -24.93%
- Market cap: $160.6B | Forward P/E: 15.22 | Beta: 0.62 | 52-week: $81.97-$137.49
- Analyst target: $116.72 (25 analysts) | Recommendation: Buy
- Next earnings: July 16, 2026 (EPS est $1.28, revenue est $12.52B)
- Real-world TriClip validation and MitraClip's ESC 2025 Class I upgrade for ventricular SMR are franchise positives not yet reflected in share performance.
Boston Scientific (BSX)
- Close: $43.06 (+0.89%); 6-month: -54.53%
- Market cap: $64.0B | Forward P/E: 11.57 | Beta: 0.56 | 52-week: $42.25-$109.50
- Analyst target: $75.00 (29 analysts) | Recommendation: Strong Buy
- Next earnings: July 29, 2026 (EPS est $0.83, revenue est $5.37B)
- ACURATE 8-year durability data offer fundamental support even as the stock trades near multi-year lows.
Anteris Technologies (AVR.AX)
- Close: A$14.00 (+2.15%); 6-month: +87.92%
- Market cap: $1.4B | Forward P/E: -6.42 | Beta: 0.73 | 52-week: $4.68-$15.00
- Analyst coverage: single analyst, target $13.00
- DurAVR platform advancing toward pivotal readouts; the stock reflects speculative optionality on a next-generation TAVR entrant.
Sector outlook: structural heart is bifurcating between the pure-play winner (Edwards) benefiting from asymptomatic-AS coverage expansion and diversified med-tech names (Boston, Abbott, Medtronic) whose valve franchises are undervalued relative to today's guideline and reimbursement trajectory. The TriClip real-world validation, ESC 2025 tricuspid upgrade, and CMS NCD together define a multi-year expansion in the addressable population that current multiples for the diversified names do not price.
Clinical Trial Updates
FDA cleared the Laplace Interventional pivotal TTVR trial, joining EVOQUE (approved) and other transcatheter tricuspid replacement platforms in active development. New York Valves 2026's TAVI NCD panel (Mack, Mehran moderating) framed the field's next inflection: how CMS's asymptomatic-AS expansion interacts with heart team infrastructure, hospital economics, and futility identification.
Social & Conference Highlights
New York Valves 2026 continues to drive the summer news cycle. TCTMD's June 2026 top-10 list shows TAVI stories dominating: EARLY TAVR 5-year data supporting TAVI in asymptomatic AS, 10-year TAVI durability signals, 7-year low-risk cohort data, TRITAVI 1-year futility findings (4% die between month 1 and 12), and the CMS NCD proposal. The consistent editorial thread: the field is expanding indications faster than long-term comparative data mature — precisely the tension the ESC 2025 acknowledged when noting that patients under 70 remain poorly represented in the pivotal RCTs supporting TAVI expansion.
Next up: Edwards' July 23 earnings will test whether TriClip real-world validation, ACURATE-class durability signals, and the CMS asymptomatic-AS NCD translate into structural heart revenue acceleration — or whether length-of-stay compression and pricing pressure blunt the volume story.